Skip to main content
Premium Trial:

Request an Annual Quote

Response Genetics

Premium
Response Genetics announced this week that its ResponseDX: Lung and ResponseDX: Colon cancer tests are now available to “select medical institutions and practice groups” through its CLIA-registered laboratory.
 
The two tests for non-small cell lung and colon cancer are PCR-based and are intended to guide treatment decisions for patients with these diseases. “The tests are in their initial launch phase and are available only to pre-qualified institutions at this time,” the company said in a statement.
 
According to the company, during this initial launch phase, Response Genetics will gather data about the clinical utility of these genetic tests.

Filed under